Previous close | 2.5600 |
Open | 2.5800 |
Bid | 2.5800 x N/A |
Ask | 2.8000 x N/A |
Day's range | 2.5800 - 2.7200 |
52-week range | 1.2100 - 9.0000 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Significant Reduction in Net Loss and Strategic Clinical Advancements
Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.